Deubiquitinating enzymes-mediated post-translational modifications of ferroptosis regulates cancer drug resistance Authors: Lili Zhang, Ming Li, Yumin Wang, Huiyan Sun, Hao Lian Published: 2026 ABSTRACT AbstractCancer drug resistance remains a formidable challenge in oncology, severely limiting the efficacy of conventional chemotherapy, targeted therapy, and immunotherapy. Ferroptosis, an iron-dependent form of regulated cell death characterized by lethal lipid peroxidation, has emerged as a critical tumor suppression mechanism and a promising avenue to overcome drug resistance. Many resistant cancer cells exhibit a marked dependency on the ferroptosis defense pathway, making them vulnerable to ferroptosis induction. Central to the regulation of ferroptosis are a suite of key positive and negative regulators. Their protein stability, activity, and subcellular localization are intricately controlled by post-translational modifications (PTMs). Among these, deubiquitinating enzymes (DUBs) have surfaced as a paramount regulatory mechanism. This review systematically elaborates on how DUBs orchestrates the fate of core ferroptosis regulators by targeting them for proteasomal or lysosomal degradation, or by modulating their activity. We comprehensively summarize the burgeoning evidence of how ubiquitin-mediated modifications of the ferroptosis pathway directly contribute to the development of resistance against various anti-cancer drugs. Furthermore, we discuss the profound therapeutic implications of targeting the ubiquitin-ferroptosis axis, highlighting strategies to leverage ubiquitination pathways to re-sensitize resistant tumors to treatment. Ultimately, a deeper understanding of ubiquitination in ferroptosis regulation not only elucidates a fundamental mechanism of drug resistance but also paves the way for novel therapeutic interventions designed to eradicate treatment-resistant cancers by triggering ferroptosis.Keywords: Cancer drug resistance, Ferroptosis, Deubiquitinating enzymes, Post-translational modifications Introduction Cancer drug resistance remains a formidable obstacle in clinical oncology, leading to treatment failure and poor patient prognosis [1–3]. While resistance Cancer remains a leading cause of mortality worldwide, with drug resistance representing a formidable barrier to successful treatment and a primary cause of therapeutic failure [1, 4]. While resistance mechanisms are diverse, ranging from enhanced drug efflux to DNA damage repair activation, a growing body of evidence underscores the critical role of altered cell death pathways [5, 6]. Apoptosis has long been the focal point of cancer therapy and resistance research; however, the emergence of non-apoptotic, regulated cell death modalities has unveiled new dimensions in this complex landscape [7]. Among these, ferroptosis has garnered significant attention as a promising avenue to overcome drug-resistant cancers [6, 8, 9]. Ferroptosis is an iron-dependent form of regulated cell death driven by the excessive peroxidation of polyunsaturated fatty acids (PUFAs) within cellular membranes. This process ultimately compromises membrane integrity, leading to membrane rupture and cell death [10]. This distinct pathological process differentiates it from other forms of cell death like apoptosis, necrosis, and autophagy. The execution of ferroptosis is primarily antagonized by two central defense systems: the cystine/glutamate antiporter (System Xc-) and the selenoprotein glutathione peroxidase 4 (GPX4) [11]. The cystine-glutamate antiporter known as System Xc⁻, which functions as a heterodimer of solute carrier family 7 member 11 (SLC7A11) and SLC3A2, mediates the cellular uptake of cystine to fuel glutathione (GSH) biosynthesis. In parallel, the enzyme GPX4 harnesses GSH as a cofactor to convert lipid hydroperoxides (LOOH) into non-toxic lipid alcohols, thus averting the dangerous buildup of LOOH that would otherwise prove lethal [12]. The vulnerability of cancer cells to ferroptosis is not static but is dynamically regulated by a complex network of metabolic and signaling pathways. Intriguingly, many conventional and targeted chemotherapeutic agents, as well as radiotherapy, have been shown to induce ferroptosis, at least in part, contributing to their anti-tumor efficacy [13]. As a result, cancer cells may acquire resistance by boosting their anti-ferroptotic mechanisms, which in turn generates a selective pressure that promotes the outgrowth of ferroptosis-resistant clones under therapeutic stress [6]. Post-translational modifications (PTMs) serve as a rapid and reversible mechanism to finely tune protein stability, activity, localization, and interactions, thereby governing virtually all cellular processes [14–16]. Among the myriad of PTMs, ubiquitination has emerged as a particularly powerful regulator. This enzymatic cascade, involving E1 (activating), E2 (conjugating), and E3 (ligating) enzymes, attaches ubiquitin molecules to lysine residues on target proteins [17]. The fate of a ubiquitinated protein is dictated by the topology of the ubiquitin chain. Unlike K48-linked polyubiquitination, which primarily directs substrates to the proteasome for degradation, K63-linked chains commonly regulate signaling pathways, protein transport, and endocytic processes [18, 19]. The specificity of this system is largely conferred by the vast family of E3 ubiquitin ligases, which recognize specific substrates. Conversely, DUBs can reverse this process, adding another layer of regulation [20]. Recent advances have illuminated the profound intersection between the ubiquitin system and the core machinery of ferroptosis [15]. Key components of the ferroptotic pathway, including SLC7A11, GPX4, and nuclear factor erythroid 2-related factor 2 (NRF2), a master regulator of antioxidant response, are now recognized as direct substrates for various E3 ligases and DUBs [21]. For instance, the E3 ligase TRIM26 has been shown to promote the ubiquitination and degradation of SLC7A11, thereby sensitizing cancer cells to ferroptosis [22]. Conversely, the OTUB1 deubiquitinase can stabilize SLC7A11 and confer resistance [23]. This ubiquitin -mediated regulation provides a dynamic and responsive mechanism for cancer cells to adapt to ferroptotic stress. In the context of therapy, the administration of chemotherapeutic drugs, kinase inhibitors, or other anti-cancer agents can directly or indirectly influence the activity of these ubiquitin-regulating enzymes, thereby altering the ferroptosis threshold and shaping the drug-resistant phenotype [24]. Tumors that evolve to stabilize anti-ferroptotic proteins or destabilize pro-ferroptotic ones through aberrant ubiquitination are poised to survive conventional treatments. This review aims to synthesize the current understanding of how ubiquitination -mediated PTMs regulate ferroptosis and its pivotal role in driving cancer drug resistance. We will systematically dissect the ubiquitination landscape of core ferroptosis regulators, discuss the E3 ligases and DUBs involved, and explore the molecular crosstalk that integrates ubiquitin signaling with other pathways in resistant cancers. Furthermore, we will prospect the therapeutic potential of targeting the ubiquitin-ferroptosis axis as a novel strategy to re-sensitize refractory tumors, ultimately aiming to provide a comprehensive framework for future research and therapeutic development in this burgeoning field. Ferroptosis Ferroptosis, first described in 2012, is a regulated cell death (RCD) characterized by iron-dependent lipid peroxidation (LPO) [10, 15, 25–28]. It is defined by GSH depletion, reduced cystine uptake, and iron-mediated LPO [10]. Early research showed that certain anticancer agents could trigger this process, which subsequently motivated the development of ferroptosis inhibitors and the identification of key pathway components [29]. Ferroptosis initiation relies on three central elements: oxidized lipid formation, reactive oxygen species (ROS) generation, and lipid peroxide activity [30] (Fig. 1). A critical imbalance between pro-ferroptotic (oxidant) and anti-ferroptotic (antioxidant) systems leads to lethal LOOH accumulation, disrupting membrane integrity and causing lytic cell damage [13, 31–33]. Schematic diagram of the core ferroptosis signaling cascade. This figure illustrates the key prerequisites, execution mechanisms, and major cellular defense systems against ferroptosis, including the iron-dependent lipid peroxidation process and the primary anti-ferroptotic pathways such as the GPX4-GSH axis, the FSP1-CoQH₂ system, and other recently identified surveillance mechanisms Prerequisites for ferroptosis Three cellular conditions are essential for ferroptosis: available iron, metabolism of polyunsaturated fatty acid-containing phospholipids (PUFA-PLs), and mitochondrial involvement [13, 34–36]. Iron-dependent lipid peroxidation Ferroptosis is executed through phospholipid peroxidation, a process requiring PUFA-PLs, iron, and ROS [10, 37, 38]. The oxidation and buildup of lipids —especially PUFA-PLs—drive cell death [33, 39]. The essential role of iron is demonstrated by the protective effect of iron chelators [37, 38, 40]. Both enzymatic and non-enzymatic mechanisms can peroxidize PUFA-PLs, which are highly oxidation-sensitive [32]. LPO proceeds through three stages: initiation, propagation, and termination [41, 42]. The integration of peroxidized PUFAs into membrane phospholipids is a key step in promoting ferroptosis [43, 44]. Enzymes such as ACSL4 and LPCAT3 mediate PUFA incorporation into phospholipids. Oxidizing enzymes —including lipoxygenases (e.g., ALOX15), cytochrome P450 reductase (POR), NADPH oxidases (NOXs), and NADH-cytochrome b5 reductase (CYB5R1) —generate oxidants that fuel LPO [45–52]. Mitochondria further contribute by producing peroxidation-promoting ROS [35, 53]. The interaction between iron and lipids yields peroxidized PUFA-PLs (LOOH) and reactive byproducts such as 4-HNE and MDA [33]. The role of iron in ferroptosis Iron drives LPO through two main mechanisms: acting as a cofactor for iron-dependent peroxidases (e.g., ALOXs and POR) and participating in the non -enzymatic Fenton reaction [13, 39, 54, 55]. In enzymatic LPO, Fe²⁺ activates peroxidases that dioxygenate PUFA-PLs in cellular membranes [56, 57]. This process begins with ACSL4 activating free PUFAs to form PUFA-CoAs, which are then esterified into phospholipids by LPCAT3 to generate PUFA-PLs [43, 44, 58]. Iron and oxygen allow POR and ALOX enzymes to peroxidize PUFA-PLs into PUFA-PL -OOH [32, 48, 52]. For detailed lipid metabolism in ferroptosis, see recent reviews [30, 41, 59]. In the non-enzymatic pathway, iron catalyzes the Fenton reaction, converting H₂O₂ into hydroxyl radicals (HO•) [41]. These radicals extract hydrogen atoms from PUFA-PLs, initiating a peroxidation chain reaction that yields PUFA-PL -OOH [60–62]. These LOOH can react with Fe²⁺ to form lipid peroxyl radicals (LOO•), which propagate LPO by oxidizing nearby lipid chains [63]. Conditions that increase the labile iron pool—such as ferroportin inhibition [64–66], elevated transferrin uptake [67], or ferritinophagy [68, 69]—enhance cellular susceptibility to ferroptosis [39]. Defense mechanisms against ferroptosis Cells utilize multiple surveillance systems to limit LPO and prevent ferroptosis [55]. These antioxidant defenses operate through GPX4-dependent and GPX4-independent pathways, often with distinct subcellular localization [25]. GPX4-GSH axis The GPX4-glutathione axis is the primary and best-characterized ferroptosis defense system [13, 70]. GPX4, a key glutathione peroxidase, prevents LOOH accumulation [10, 11, 63, 71, 72]. It exists in three isoforms localized to the cytosol, mitochondria, and nucleus. Both cytosolic and mitochondrial GPX4 suppress ferroptosis, while the nuclear isoform’s role remains unclear [29]. GPX4 acts as a lipid repair enzyme [73, 74], reducing toxic LOOH to harmless PUFA-PL-OH while oxidizing GSH to GSSG [75, 76]. GPX4 function depends on System Xc−, which imports cystine for GSH synthesis [38, 77, 78]. FSP1-CoQH₂ system The FSP1-coenzyme Q₁₀ (CoQ₁₀) system represents a second, GPX4-independent ferroptosis suppression pathway. Located at the plasma membrane, FSP1 reduces CoQ₁₀ to ubiquinol (CoQH₂) using NADPH. CoQH₂ acts as a lipophilic antioxidant that inhibits LPO and protects membranes [79–81]. FSP1 also recruits ESCRT-III machinery to repair plasma membrane damage [82, 83]. GCH1-BH₄ system GTP cyclohydrolase 1 (GCH1) and its product tetrahydrobiopterin (BH₄) constitute a third ferroptosis defense pathway [84, 85]. BH₄ acts as a radical-trapping antioxidant that suppresses LPO. GCH1 exerts anti-ferroptotic effects both by generating BH₄ and by remodeling cellular lipids—depleting peroxidation-sensitive PUFA-PLs and increasing levels of reduced CoQ₁₀ [27]. DHODH-CoQH₂ system Dihydroorotate dehydrogenase (DHODH) forms a mitochondria-specific ferroptosis defense system [86]. This inner mitochondrial membrane enzyme reduces CoQ₁₀ to CoQH₂ during pyrimidine biosynthesis. By regenerating mitochondrial ubiquinol, DHODH detoxifies mitochondrial LPO, particularly when GPX4 is impaired [86]. MBOAT1/2–MUFA system A recently identified GPX4- and FSP1-independent pathway involves membrane -bound O-acyltransferases MBOAT1 and MBOAT2 [87]. These enzymes incorporate monounsaturated fatty acids (MUFAs) into phosphatidylethanolamine (PE), increasing PE-MUFA and decreasing peroxidation-prone PE-PUFA. This remodeling reduces ferroptosis sensitivity. MBOAT1 and MBOAT2 expression is regulated by estrogen and androgen receptors, respectively [87]. SC5D–7-DHC axis The most recently discovered anti-ferroptotic pathway involves lathosterol oxidase (SC5D) and its product 7-dehydrocholesterol (7-DHC) [88, 89]. 7-DHC, a cholesterol synthesis intermediate found in membranes and mitochondria, functions as a radical -trapping antioxidant that diverts peroxidation away from phospholipids, thereby attenuating ferroptosis. Regulation of ferroptosis in cancer Ferroptosis has emerged as a critical tumor suppression mechanism and a promising avenue for cancer therapy. The sensitivity of cancer cells to ferroptosis is not static but is intricately regulated by a complex network of intracellular signals. Among these, epigenetic modifications and PTMs serve as pivotal layers of control, fine-tuning the expression and activity of key components within the ferroptotic cascade. This section delves into how these reversible modifications govern the ferroptotic landscape in cancer. Epigenetic regulation of ferroptosis Through processes such as DNA methylation and histone modifications, epigenetic regulation modulates gene expression independently of changes in the DNA sequence itself, thereby playing a decisive role in determining cellular sensitivity to ferroptosis. DNA Methylation: The methylation of CpG islands in gene promoter regions can lead to transcriptional silencing. A prime example is the promoter methylation of the GPX4 gene. GPX4 is the primary enzyme responsible for reducing LOOH, thus acting as the central ferroptosis suppressor. In certain cancer types, hypermethylation of the GPX4 promoter leads to its reduced expression, rendering these cells more vulnerable to ferroptosis inducers [11]. Conversely, the dysregulation of other genes involved in iron metabolism or antioxidant defense via DNA methylation can similarly modulate ferroptotic thresholds. For instance, the SLC7A11, a key component of the cystine/glutamate antiporter system xc-, is frequently regulated by epigenetic mechanisms. Its overexpression, sometimes due to promoter hypomethylation, can confer ferroptosis resistance in several cancers [90]. Histone modifications: The dynamic modification of histone tails, such as acetylation, methylation, and ubiquitination, alters chromatin accessibility and gene transcription. Histone deacetylases (HDACs) have been implicated in ferroptosis regulation. HDAC inhibitors can promote ferroptosis in some contexts by modulating the expression of genes involved in iron homeostasis and lipid metabolism [91]. Specifically, the suppression of HDACs can lead to hyperacetylation of histones at the promoters of pro-ferroptotic genes, facilitating their transcription. Furthermore, histone methyltransferases and demethylases are involved. For example, the H3K9-specific methyltransferase G9a can repress the expression of genes like Ferroptosis Suppressor Protein 1 (FSP1), a GPX4-independent ferroptosis defense system, in a context-dependent manner [81]. The complex interplay of different histone marks provides a nuanced regulatory network that integrates various signals to determine cell fate upon ferroptotic stress. Non-coding RNAs: While not a classical “epigenetic mark” per se, non-coding RNAs, particularly microRNAs (miRNAs), are crucial epigenetic regulators. Numerous miRNAs have been identified as direct modulators of ferroptosis. For instance, miR-137 directly targets SLC7A11 mRNA, leading to its degradation and consequently sensitizing glioma cells to ferroptosis [92]. m⁶A RNA methylation: This epitranscriptomic modification regulates mRNA stability and translation of ferroptosis genes.In NSCLC, METTL3-mediated m⁶A modification stabilizes SLC7A11 mRNA, promoting ferroptosis resistance220220. YTHDC2, an m⁶A reader, promotes decay of SLC7A11 mRNA, enhancing ferroptosis [93]. In HCC, IGF2BP3 stabilizes Nrf2 mRNA via m⁶A, inhibiting sorafenib-induced ferroptosis [94]. Post-translational modifications in ferroptosis regulation PTMs provide a rapid and reversible mechanism to control the stability, localization, and activity of proteins central to the ferroptosis pathway. Ferroptosis’s regulation is profoundly influenced by post-translational modifications (PTMs), which dynamically modulate the stability, activity, and localization of key ferroptosis-related proteins. These modifications offer novel insights into cancer progression and therapeutic resistance. Phosphorylation: Kinase-mediated phosphorylation is a central switch. As a key sensor of cellular energy status, AMP-activated protein kinase (AMPK) suppresses lipid synthesis by phosphorylating and thereby inactivating acetyl-CoA carboxylase (ACC), the enzyme that dictates the rate of fatty acid production. This phosphorylation reduces the pool of polyunsaturated fatty acids (PUFAs) available for peroxidation, thereby suppressing ferroptosis [95]. Conversely, other kinases can promote ferroptosis. For example, phosphorylation of BECN1 by AMPK enhances its interaction with SLC7A11, leading to system xc- inhibition and ferroptosis sensitization [96]. Phosphorylation regulates ferroptosis by modulating enzyme activity and protein interactions. In CRC, AMPK phosphorylates BECN1, which then binds to and inhibits SLC7A11, promoting ferroptosis [16, 97]. In HCC, AKT phosphorylates creatine kinase B (CKB), which in turn phosphorylates GPX4 at S104, preventing its degradation via chaperone-mediated autophagy and inhibiting ferroptosis [98]. In breast cancer, PKCβII phosphorylates ACSL4, amplifying lipid peroxidation and ferroptosis7777. In NSCLC, inhibition of system Xc⁻ leads to glutamate accumulation, which activates ADCY and PKA, suppressing YAP and promoting ferroptosis [99]. Acetylation: Acetylation, particularly of transcription factors and histones, significantly influences ferroptosis. In NSCLC, acetylation of p53 at specific lysine residues is essential for its ability to repress SLC7A11 and induce ferroptosis [100, 101]. The acetylation-defective mutant p53³KR retains ferroptosis-inducing capacity, highlighting the importance of acetylation in p53-mediated tumor suppression [101]. In HCC, HMGCL increases β-hydroxybutyrate (β-OHB)-mediated acetylation of H3K9, enhancing DPP4 expression and sensitizing cells to ferroptosis [102]. In glioma, KAT6B acetylates histones to promote STAT3 expression, which in turn suppresses ferroptosis [103]. Methylation: DNA and histone methylation regulate the expression of ferroptosis-related genes. In gastric cancer, DNA methylation silences ELOVL5 and FADS1 in intestinal-type GCs, rendering them resistant to ferroptosis [104]. In NSCLC, low DNA methylation and high H3K4me3/H3K27ac levels at the GPX4 promoter lead to its overexpression, conferring ferroptosis resistance [105]. In acute lymphoblastic leukemia (ALL), hypermethylation of the FSP1 promoter silences its expression, creating dependency on the GSH-GPX4 axis and increasing sensitivity to ferroptosis inducerss [106]. O-GlcNAcylation: This nutrient-sensitive PTM links metabolic flux to ferroptosis regulation. In HCC, O-GlcNAcylated c-Jun antagonizes ferroptosis by promoting GSH synthesis via PSAT1 and CBS transcription205205. Conversely, O-GlcNAcylation of YAP increases TFRC expression and ferroptosis sensitivity [107]. In pancreatic cancer, O-GlcNAcylation of ZEB1 induces FASN and FADS2, promoting lipid peroxidation and ferroptosis in mesenchymal cells [108]. SUMOylation: SUMOylation affects protein stability and function in ferroptosis. In lung cancer, elevated SENP1 promotes A20 SUMOylation, which downregulates ACSL4 and upregulates SLC7A11, inhibiting ferroptosis214214. In GBM, HSP27 induces SUMOylation of ACSL4, reducing its stability and suppressing ferroptosis [109]. In conclusion, PTMs such as phosphorylation, ubiquitination, acetylation, methylation, O-GlcNAcylation, SUMOylation, and m⁶A RNA methylation intricately regulate ferroptosis in cancer by targeting key players like SLC7A11, GPX4, ACSL4, Nrf2, and p53. These modifications not only influence cancer cell susceptibility to ferroptosis but also offer promising targets for overcoming therapeutic resistance. Combining PTM-targeting agents with ferroptosis inducers may represent a novel strategy for cancer treatment. The interplay between epigenetic and post-translational modifications constitutes a sophisticated regulatory code that governs ferroptosis in cancer. Epigenetic mechanisms set the long-term transcriptional potential of the ferroptosis network, while PTMs allow for rapid, signal-responsive adjustments. The reversible nature of these modifications makes them attractive therapeutic targets. Pharmacological manipulation of these pathways—using HDAC inhibitors, deubiquitinase inhibitors, or kinase modulators—holds immense promise for selectively inducing ferroptosis in cancer cells, thereby overcoming drug resistance and improving therapeutic outcomes. DUBs regulate ferroptosis in cancer drug resistance Despite the remarkable diversity of cancer types and therapeutic contexts, the emerging literature reveals that deubiquitinating enzymes (DUBs) regulate ferroptosis and drug resistance through several highly recurrent mechanistic themes. First, the most prevalent pattern is the direct deubiquitination and stabilization of core anti-ferroptotic gatekeepers, particularly SLC7A11 and GPX4. DUBs such as USP20, OTUB1, OTUD5, and USP14 remove K48-linked polyubiquitin chains from these proteins, shielding them from proteasomal degradation and thereby reinforcing the cystine–GSH–GPX4 antioxidant axis. This mechanism operates across hepatocellular carcinoma, colorectal cancer, bladder cancer, lung cancer, multiple myeloma, and melanoma, indicating a conserved survival strategy. Second, DUBs frequently target master transcription factors that orchestrate ferroptosis defense programs. For example, USP11 stabilizes NRF2 to upregulate antioxidant gene expression, while USP2 and the USP22–MDM2 axis modulate p53 stability, which in turn represses SLC7A11 transcription. These transcription-centric mechanisms allow DUBs to exert broad, coordinated effects on ferroptosis sensitivity. Third, DUBs regulate ferroptosis via metabolic remodeling, including lipid metabolism (USP7–SCD, USP14–FASN), iron metabolism (USP22–TFRC, USP2–NCOA4–ferritinophagy), and mitochondrial function (USP30–TOMM40). Fourth, non-canonical mechanisms—such as USP5 promoting YBX3 lysosomal degradation to indirectly stabilize SLC7A11, or ZRANB1 functioning paradoxically as an E3 ligase for SLC7A11—highlight the functional versatility of DUB family members. Finally, DUB activity is often modulated by upstream stress signals (e.g., DNA damage-induced ATR phosphorylation of USP20, hypoxia-induced downregulation of USP2, or palmitoylation of USP19), creating dynamic feedback loops that adapt ferroptosis threshold to therapeutic pressure. Collectively, these common patterns establish that DUBs act as central nodes in a cross-cancer regulatory network that suppresses ferroptosis to enable drug resistance, providing a rational foundation for developing broad-spectrum DUB-targeted therapies. The following sections will delineate how these unified principles manifest in specific cancer types(Table 1). Table 1Overview of DUBs regulating ferroptosis in in cancer drug resistanceDUBCancersTarget proteinRole in drug resistanceModel systemClinical significance (TCGA/GEO/prognosis)Ref.USP20HCCSLC7A11Stabilizes SLC7A11, inhibits ferroptosis, confers oxaliplatin resistanceCell lines, mouse xenograftsHigh USP20 expression correlates with poor prognosis and reduced overall survival (OS) in HCC patients.[110]COPS5HCCMK2Stabilizes MK2-HSPB1 axis, suppresses ferroptosis, confers sorafenib resistanceCell lines, mouse xenograftsCOPS5 overexpression linked to shorter OS and disease-free survival (DFS) in sorafenib-treated HCC.[111]USP14HCCGPX4Stabilizes GPX4, inhibits ferroptosis, confers radiotherapy resistanceCell lines, mouse xenograftsHigh USP14/GPX4 expression associated with radioresistance and poor prognosis in HCC patients.[112]USP18HCCNCOA4Promotes NCOA4 deISGylation/degradation, inhibits ferritinophagy & ferroptosis, confers sorafenib resistanceCell lines, mouse xenograftsElevated USP18 correlates with acquired sorafenib resistance and reduced OS in HCC.[113]USP8HCCβ-cateninStabilizes β-catenin, upregulates GPX4, suppresses ferroptosis, confers erastin resistanceCell lines, mouse xenograftsHigh USP8/β-catenin expression associated with aggressive tumor features and poor survival.[114]USP22HCCH2BK120ubRepresses TFRC transcription, reduces iron uptake, inhibits ferroptosis, confers sorafenib resistanceCell lines, mouse xenograftsUSP22 overexpression predicts poor prognosis and sorafenib resistance in HCC patients.[115]OTUB1CRCGPX4Stabilizes GPX4, inhibits ferroptosis, confers general therapy resistanceCell lines, mouse xenograftsHigh OTUB1/GPX4 expression correlates with reduced OS and chemoresistance in CRC.[116]USP5CRCYBX3Promotes YBX3 lysosomal degradation, stabilizes SLC7A11, inhibits ferroptosisCell lines, mouse xenograftsHigh USP5/low YBX3 expression linked to poor prognosis and resistance to 5-FU/oxaliplatin.[117]USP7GCSCDStabilizes SCD, inhibits lipid peroxidation & ferroptosis, confers therapy resistanceCell lines, mouse xenograftsHigh USP7/SCD expression associated with poor survival and chemoresistance in gastric cancer.[118]USP24Lung cancer/ GBMGPX4, DHFRStabilizes GPX4/DHFR, inhibits ferroptosis, confers TMZ/taxol resistanceCell lines, mouse xenograftsHigh USP24 expression predicts poor OS and resistance to TMZ (GBM) and taxol (lung cancer).[119]USP11LUAD (KLK)NRF2Stabilizes NRF2, enhances GSH synthesis, inhibits ferroptosisCell lines, mouse xenograftsHigh USP11/NRF2 expression associated with aggressive disease and poor prognosis in LUAD.[120]USP2NSCLCp53Stabilizes p53, suppresses SLC7A11, promotes ferroptosis, reverses cisplatin resistanceCell lines, mouse xenograftsLow USP2 expression correlates with cisplatin resistance and shorter OS in NSCLC patients.[121]USP3NSCLCACOT7Stabilizes ACOT7, inhibits ferroptosis, confers cisplatin resistanceCell linesHigh USP3/ACOT7 expression linked to poor response to cisplatin and reduced DFS.[122]USP22NSCLCMDM2Stabilizes MDM2, promotes p53 degradation, inhibits ferroptosis, confers gefitinib resistanceCell lines, mouse xenograftsHigh USP22/MDM2 correlates with gefitinib resistance and poor prognosis in EGFR-mutant NSCLC.[123]USP2ESCCNCOA4Stabilizes NCOA4, promotes ferritinophagy & ferroptosis; loss under hypoxia confers resistanceCell lines, mouse xenograftsLow USP2 expression in hypoxic regions correlates with therapy resistance and poor OS in ESCC.[124]USP14ESCCGPX4Deubiquitinates & stabilizes GPX4, inhibits ferroptosis, confers general resistanceCell lines, mouse xenograftsHigh USP14/GPX4 expression associated with poor prognosis and chemoradioresistance.[125]USP14HNSCCFABP5Stabilizes FABP5, upregulates SLC7A11/GPX4, inhibits ferroptosis, confers cisplatin resistanceCell lines, mouse xenograftsHigh USP14/FABP5 expression correlates with cisplatin resistance and reduced OS in HNSCC.[126]UCHL1NPCCAV1Stabilizes CAV1, inhibits ferroptosis, confers docetaxel resistanceCell lines, mouse xenograftsHigh UCHL1/CAV1 expression associated with docetaxel resistance and poor prognosis in NPC.[127]USP14NPCFASNStabilized by GSTM3, promotes FASN & lipid peroxidation; loss confers radioresistanceCell lines, mouse xenograftsLow GSTM3/high USP14 expression correlates with radioresistance and poor survival in NPC.[128]USP30Breast cancerTOMM40Stabilizes TOMM40, inhibits ferroptosis, confers tamoxifen resistanceCell lines, mouse xenograftsHigh USP30/TOMM40 expression linked to tamoxifen resistance and poor OS in ER+ breast cancer.[129]OTUD5TNBCSLC7A11Stabilizes SLC7A11, inhibits ferroptosis, confers paclitaxel resistanceCell lines, mouse xenograftsHigh OTUD5/SLC7A11 correlates with paclitaxel resistance and reduced DFS in TNBC patients.[130]USP31Cervical cancerGPX4Stabilizes GPX4, inhibits ferroptosis, confers radioresistanceCell lines, mouse xenograftsHigh USP31/GPX4 expression associated with radioresistance and poor prognosis in cervical cancer.[131]USP19CRPCACSL4Palmitoylation impairs ACSL4 stabilization, inhibits ferroptosis, confers enzalutamide resistanceCell lines, mouse xenograftsHigh ZDHHC2/low ACSL4 expression correlates with enzalutamide resistance and poor OS in CRPC.[132]OTUB1Bladder cancerSLC7A11Stabilizes SLC7A11, inhibits ferroptosis, promotes stemness & drug resistanceCell lines, mouse xenograftsHigh OTUB1/SLC7A11 associated with cancer stemness, chemoresistance, and poor prognosis in BCa.[133]ZRANB1RCCCSLC7A11Acts as E3 ligase for SLC7A11 (non-canonical), promotes degradation, loss confers resistanceCell lines, mouse xenograftsLow ZRANB1/high SLC7A11 expression predicts ferroptosis resistance and poor OS in RCCC.[134]USP14Multiple myelomaSLC7A11Stabilizes SLC7A11 via HSPA9, inhibits ferroptosis, confers therapy resistanceCell lines, mouse xenograftsHigh HSPA9/USP14/SLC7A11 expression correlates with poor OS and drug resistance in MM patients.[135]BAP1Uveal melanomaPPARγLoss of BAP1 disrupts lipid metabolism, confers ferroptosis resistance in metastatic UMCell lines, mouse xenografts, patient samplesBAP1 loss correlates with metastatic progression, lipotoxicity resistance, and poor prognosis in UM.[136]USP7MelanomaJunDStabilizes JunD, promotes AIFM2 (FSP1) expression, inhibits ferroptosisCell lines, mouse xenograftsHigh USP7/JunD/AIFM2 expression associated with ferroptosis resistance and reduced OS in melanoma.[137]USP14MelanomaGPX4Stabilizes GPX4, inhibits ferroptosis, confers vemurafenib resistanceCell lines, mouse xenograftsHigh USP14/GPX4 correlates with vemurafenib resistance and poor prognosis in BRAF-mutant melanoma.[138]BC: Breast Cancer; BCa: Bladder Cancer; CC: Cervical Cancer; CRC: Colorectal Cancer; ESCC: Esophageal Squamous Cell Carcinoma; GC: Gastric Cancer; GBM: Glioblastoma; HCC: Hepatocellular Carcinoma; HNSCC: Head and Neck Squamous Cell Carcinoma; LUAD: Lung Adenocarcinoma; NSCLC: Non-Small Cell Lung Cancer; UM: Uveal Melanoma; TNBC: Triple-Negative Breast Cancer; MM: Multiple Myeloma; NPC: Nasopharyngeal Carcinoma; CRPC: Prostate Cancer; RCCC: Renal Clear Cell Carcinoma Overview of DUBs regulating ferroptosis in in cancer drug resistance BC: Breast Cancer; BCa: Bladder Cancer; CC: Cervical Cancer; CRC: Colorectal Cancer; ESCC: Esophageal Squamous Cell Carcinoma; GC: Gastric Cancer; GBM: Glioblastoma; HCC: Hepatocellular Carcinoma; HNSCC: Head and Neck Squamous Cell Carcinoma; LUAD: Lung Adenocarcinoma; NSCLC: Non-Small Cell Lung Cancer; UM: Uveal Melanoma; TNBC: Triple-Negative Breast Cancer; MM: Multiple Myeloma; NPC: Nasopharyngeal Carcinoma; CRPC: Prostate Cancer; RCCC: Renal Clear Cell Carcinoma Gastrointestinal cancers In gastrointestinal cancers, deubiquitinating enzymes (DUBs) critically mediate drug resistance by regulating key ferroptosis effectors, thereby enabling tumor cells to evade therapy-induced cell death. This section examines how specific DUBs, such as USP20, COPS5, USP14, and OTUB1, modulate the stability of proteins like SLC7A11, GPX4, and NCOA4 in cancers including hepatocellular carcinoma(HCC), colorectal cancer, and gastric cancer, ultimately suppressing ferroptosis and promoting resistance to chemotherapy and targeted agents (Fig. 2). DUB-mediated regulation of ferroptosis in gastrointestinal cancers contributes to drug resistance. This diagram summarizes the specific deubiquitinating enzymes (DUBs), their target proteins, and the resulting ferroptosis suppression mechanisms that confer resistance to chemotherapy, targeted therapy, and radiotherapy in gastrointestinal malignancies, including hepatocellular carcinoma (HCC), colorectal cancer (CRC), gastric cancer (GC), and esophageal squamous cell carcinoma (ESCC) In Hepatocellular Carcinoma (HCC), multiple DUBs have been identified as central players in conferring resistance to various agents by suppressing ferroptosis. A prominent example is USP20, which drives oxaliplatin (OXA) resistance [110]. The mechanism involves USP20 directly interacting with and deubiquitinating SLC7A11. By removing K48-linked polyubiquitin chains, USP20 prevents the proteasomal degradation of SLC7A11. This stabilization ensures sustained cystine uptake and glutathione (GSH) synthesis, thereby empowering GPX4 to detoxify LOOH and inhibit ferroptosis [110]. Furthermore, this pathway is amplified by a positive feedback loop where DNA damage from chemotherapy activates the kinase ATR, which phosphorylates and stabilizes USP20 itself, creating a robust survival axis linking the DNA damage response to ferroptosis evasion [110]. Similarly, resistance to the multi-kinase inhibitor sorafenib in HCC is mediated by several DUBs through distinct but converging pathways. COPS5 (COP9 signalosome subunit 5) promotes sorafenib resistance by stabilizing the MK2-HSPB1 signaling axiss [111]. COPS5 deubiquitinates and stabilizes Mitogen-Activated Protein Kinase 2 (MK2), leading to enhanced phosphorylation of Heat Shock Protein Beta-1 (HSPB1). Phospho-HSPB1 acts as a ferroptosis repressor by reducing intracellular iron accumulation and lipid peroxidation. Sorafenib itself can upregulate COPS5 via ATF4, reinforcing this resistance pathway [111]. Another key DUB, USP18, contributes to acquired sorafenib resistance by negatively regulating ferritinophagy, a process that releases iron for ferroptosis execution [113]. USP18 promotes the deISGylation of Nuclear Receptor Coactivator 4 (NCOA4), a cargo receptor for ferritinophagy. This modification leads to increased NCOA4 ubiquitination and degradation, impairing iron release from ferritin, reducing the labile iron pool, and consequently suppressing sorafenib-induced ferroptosis [113]. Furthermore, radiotherapy resistance in HCC is linked to USP14 [112]. Upon ionizing radiation (IR), a complex involving TRIM14 recruits USP14 to GPX4. USP14 then cleaves K48-linked ubiquitin chains on GPX4, preventing its degradation. By maintaining GPX4 stability and activity, USP14 ensures efficient reduction of LOOH, protecting HCC cells from radiation-induced ferroptosis [112]. Additionally, resistance to ferroptosis inducers like erastin involves USP8 [114]. USP8 stabilizes β-catenin by deubiquitination, leading to its nuclear translocation and activation of Wnt/β-catenin signaling. This cascade results in the upregulation of downstream targets including GPX4, thereby enhancing the antioxidant defense and inhibiting ferroptosis [114]. Beyond stabilizing cytoplasmic proteins, DUBs can also exert epigenetic control to regulate ferroptosis susceptibility. In HCC, USP22 promotes sorafenib resistance through a histone-modifying mechanism [115]. Functioning as a histone deubiquitinase, USP22 removes monoubiquitination from histone H2B at lysine 120 (H2BK120ub). This action suppresses the transcription elongation of the Transferrin Receptor (TFRC) gene, limiting iron import. Reduced iron uptake diminishes the labile iron pool, thereby inhibiting lipid peroxidation and ferroptosis, which contributes to sorafenib resistance [115]. Transitioning to colorectal Cancer (CRC), DUB-mediated ferroptosis resistance also plays a pivotal role. OTUB1 is a critical regulator that promotes therapy resistance by directly stabilizing GPX4 [116]. OTUB1 interacts with GPX4 and removes its ubiquitin chains, markedly enhancing GPX4 protein stability. This action maintains GPX4’s function in reducing LOOH, allowing CRC cells to survive under oxidative stress and resist ferroptosis-induced cell death, thereby contributing to general therapy resistance [116]. Moreover, a novel and non-canonical mechanism is employed by USP5 in CRC [117]. Unlike typical deubiquitinase activity, USP5 promotes ferroptosis resistance independently of its catalytic function. USP5 physically interacts with YBX3 (Y-box binding protein 3) and facilitates its degradation via the autophagy-lysosomal pathway. Under normal conditions, YBX3 promotes the lysosomal degradation of SLC7A11. Therefore, by mediating YBX3 degradation, USP5 indirectly stabilizes SLC7A11 protein levels [117]. This stabilization enhances System Xc- activity, bolstering GSH synthesis and the cellular defense against lipid peroxidation and ferroptosis [117]. This USP5/YBX3/SLC7A11 axis underscores the diversity of strategies DUBs use to regulate ferroptosis [117]. In gastric cancer (GC), the deubiquitinase USP7 has been implicated in therapy resistance by inhibiting ferroptosis [118]. Through direct physical association, USP7 enhances the stability of Stearoyl-CoA Desaturase (SCD)—a critical enzyme driving the synthesis of monounsaturated fatty acids. By preventing SCD degradation, USP7 ensures a high level of monounsaturated fatty acids, which are less prone to peroxidation compared to polyunsaturated fatty acids. This remodeling of cellular lipid composition suppresses lipid peroxidation and ferroptosis. Inhibition of USP7 leads to SCD degradation, accumulation of lipid reactive oxygen species, and sensitization to ferroptosis, underscoring the importance of the USP7-SCD axis in GC cell survival and drug resistance [118]. Finally, in esophageal squamous cell carcinoma (ESCC), DUBs regulate ferroptosis in response to microenvironmental stress and oncogenic signaling. USP2 is a key regulator whose function is modulated by hypoxia [124]. Under normoxic conditions, USP2 stabilizes NCOA4 via deubiquitination, promoting ferritinophagy, increasing the labile iron pool, and sensitizing cells to ferroptosis. However, hypoxia downregulates USP2 expression, leading to NCOA4 degradation, suppressed ferritinophagy, and inhibition of ferroptosis, thereby conferring resistance. This mechanism links tumor microenvironmental stress directly to DUB-mediated ferroptosis regulation [124]. Furthermore, in ESCC, the oncogenic kinase PKCι phosphorylates and activates USP14 [125]. Activated USP14 then deubiquitinates GPX4, specifically reducing its K63-linked ubiquitination. This modification stabilizes GPX4 by blocking its recognition by the autophagy-lysosome pathway, enhancing the antioxidant defense and inhibiting ferroptosis. This PKCι-USP14-GPX4 axis establishes a positive feedback loop that reinforces ferroptosis resistance in ESCC [125]. In Gastric Cancer (GC), the deubiquitinase USP7 has been identified as a mediator of therapy resistance through lipid metabolism reprogramming [118]. USP7 directly interacts with and deubiquitinates SCD, a key enzyme in MUFA synthesis. By stabilizing SCD, USP7 increases MUFA levels, which are incorporated into phospholipids, reducing the abundance of peroxidation-prone PUFAs [118]. This lipid remodeling suppresses lipid peroxidation and protects gastric cancer cells from ferroptotic death. Inhibition of USP7 leads to SCD degradation, accumulation of LOOH, and sensitization to ferroptosis, impairing tumor growth and metastasis [118]. In summary, across gastrointestinal cancers, DUBs emerge as master regulators of ferroptosis-mediated drug resistance through multifaceted mechanisms. In HCC, a repertoire of DUBs (USP20, COPS5, USP14, USP18, USP8, USP22) targets various aspects of the pathway, from cystine import and GPX4 activity to iron metabolism and epigenetic regulation. In CRC, OTUB1 and USP5 converge on stabilizing the core defense machinery, either directly (GPX4) or indirectly (SLC7A11). In GC, USP7 acts by altering lipid composition via SCD stabilization. In ESCC, DUB activity is influenced by hypoxia (USP2) and oncogenic kinase signaling (USP14), adapting ferroptosis sensitivity to external and internal cues. These studies collectively underscore the DUB-ferroptosis axis as a critical vulnerability and a promising therapeutic target for overcoming resistance in gastrointestinal malignancies. Future efforts to develop selective DUB inhibitors or strategies to disrupt these specific interactions could effectively resensitize these cancers to standard therapies by reinstating ferroptotic cell death. Lung cancer This section elucidates how specific DUBs regulate ferroptosis to mediate drug resistance across various lung cancer subtypes, including non-small cell lung cancer (NSCLC) and lung adenocarcinoma. It highlights key DUB-substrate axes that stabilize anti-ferroptotic proteins or degrade pro-ferroptotic factors, thereby enabling cancer cells to evade therapy-induced cell death (Fig. 3). The role of DUBs in regulating ferroptosis to drive therapy resistance in lung cancers and head & neck tumors. This figure delineates the context-specific DUB-ferroptosis regulatory axes identified in lung cancer subtypes (e.g., NSCLC, LUAD) and head & neck tumors (HNSCC, NPC), highlighting how the stabilization of key anti-ferroptotic proteins or degradation of pro-ferroptotic factors underpins resistance to agents like cisplatin, gefitinib, taxol, and radiotherapy A prominent example is the deubiquitinase USP24, which mediates a broad-spectrum defense against ferroptosis, thereby conferring resistance to chemotherapeutic agents like temozolomide (TMZ) and Taxol in lung cancer and glioblastoma models [119]. The mechanism is multifaceted, centering on the simultaneous stabilization of multiple critical anti-ferroptotic proteins. USP24 directly binds to and deubiquitinates GPX4, the primary enzyme responsible for reducing LOOH, preventing its degradation. Furthermore, USP24 stabilizes dihydrofolate reductase (DHFR), a component of the GCH1/BH4 antioxidant axis that also suppresses ferroptosis [119]. This dual stabilization creates a robust, coordinated cellular defense system. Intriguingly, USP24 also stabilizes a subset of ABCG transporters involved in cholesterol homeostasis. The pharmacological inhibition of USP24 by the small molecule NC1677397 disrupts this entire network. It induces the degradation of GPX4 and DHFR, likely via autophagy, while simultaneously upregulating the pro-ferroptotic driver ACSL4, which enriches membranes with peroxidizable lipids [119]. The consequent depletion of antioxidant defenses, coupled with increased substrate availability for peroxidation, creates a potent pro-ferroptotic state that overcomes drug resistance, highlighting USP24 as a master regulator of the ferroptotic threshold. Transitioning to a specific molecular subtype, the deubiquitinase USP11 is critically involved in ferroptosis resistance within KLK lung adenocarcinoma (characterized by Kras mutation with Lkb1 and Keap1 inactivation) [120]. In this context, resistance is orchestrated through the stabilization of the master antioxidant transcription factor NRF2. Under basal conditions, USP11 removes ubiquitin chains from NRF2, preventing its proteasomal degradation and ensuring high levels of NRF2-target genes, including those involved in GSH synthesis. This enhanced antioxidant capacity renders KLK LUAD cells resistant to ferroptosis. The significance of this axis is revealed by the action of the compound RSL3, which traditionally targets GPX4. Research demonstrates that RSL3 also directly binds to and inhibits USP11’s enzymatic activity [120]. This inhibition leads to NRF2 ubiquitination and degradation, downregulating the NRF2-GSH axis and sensitizing cells to ferroptosis. This mechanism operates in parallel to GPX4 inhibition, illustrating a dual-pathway strategy through which a single compound can dismantle a multi-layered ferroptosis defense system in a genetically defined aggressive lung cancer subtype [120]. In contrast, the role of USP2 in NSCLC presents a tumor-suppressive function in the context of cisplatin resistance. Studies show that USP2 expression is downregulated in cisplatin-resistant NSCLC cells [121]. Functionally, USP2 overexpression promotes ferroptosis and reverses cisplatin resistance. The molecular pathway involves USP2 directly interacting with and deubiquitinating the tumor suppressor p53 at the K305R site, thereby enhancing p53 stability and facilitating its nuclear translocation [121]. Once in the nucleus, p53 transcriptionally represses the expression of SLC7A11. The downregulation of SLC7A11 impairs cystine uptake and GSH synthesis, leading to GPX4 inactivation, lipid peroxide accumulation, and ultimately, ferroptotic cell death [121]. This USP2-p53-SLC7A11 axis underscores how the loss of a specific DUB can disable a pro-ferroptotic signaling cascade, leading to acquired chemotherapy resistance. Restoring USP2 function or mimicking its action on p53 could therefore resensitize resistant tumors [121]. Conversely, USP3 promotes cisplatin resistance in NSCLC through a mechanism that actively suppresses ferroptosis [122]. Highly expressed in resistant cells, USP3 directly deubiquitinates and stabilizes Acyl-CoA Thioesterase 7 (ACOT7), an enzyme involved in lipid metabolism [122]. The stabilized ACOT7 protein creates a cellular environment hostile to ferroptosis execution. This is evidenced by decreased levels of intracellular iron, reactive oxygen species (ROS), and MDA, alongside increased GSH. Furthermore, ACOT7 upregulation leads to decreased pro-ferroptotic ACSL4 and increased anti-ferroptotic GPX4 protein levels [122]. By stabilizing ACOT7, USP3 orchestrates a metabolic shift that reduces the accumulation of lethal LOOH, enabling cancer cell survival upon cisplatin treatment. The dependency of this resistance pathway on the USP3-ACOT7 axis was confirmed by rescue experiments, solidifying its role as a key negative regulator of ferroptosis in NSCLC [122]. Similarly, USP22 drives resistance to targeted therapy in NSCLC, specifically against the EGFR inhibitor gefitinib [123]. USP22 is overexpressed in NSCLC and exerts its pro-resistance effect by stabilizing the E3 ubiquitin ligase MDM2 through deubiquitination [123]. The elevated MDM2 protein then enhances the ubiquitination and degradation of the tumor suppressor p53. As discussed in the USP2 mechanism, p53 is a positive regulator of ferroptosis through its ability to repress SLC7A11. Therefore, the USP22-MDM2 axis leads to p53 degradation, subsequent relief of SLC7A11 repression, and ultimately, the inhibition of ferroptosis [123]. This inhibition, characterized by reduced lipid ROS and Fe²⁺ alongside increased GSH, allows NSCLC cells to evade gefitinib-induced cell death. Knocking down USP22 or MDM2 restores ferroptosis sensitivity and resensitizes cells to gefitinib, highlighting this axis as a viable target for combination therapy [123]. In summary, DUBs regulate ferroptosis-mediated drug resistance in lung cancer through highly specific, yet interconnected, molecular circuits. These enzymes primarily function by stabilizing key proteins that either directly inhibit ferroptosis (e.g., GPX4 stabilization by USP24) or control the transcription of critical ferroptosis components (e.g., NRF2 stabilization by USP11 and p53 destabilization via the USP22-MDM2 axis). The regulatory targets include core defensive enzymes (GPX4), metabolic regulators (ACOT7, DHFR), and major transcription factors (NRF2, p53). The consequence is a fortified cellular state resistant to lipid peroxidation, allowing cancer cells to survive the onslaught of chemotherapies like cisplatin and taxol, as well as targeted agents like gefitinib. Importantly, the therapeutic vulnerability exposed by these studies is that pharmacological inhibition of these specific DUBs—such as NC1677397 against USP24 or RSL3’s inhibition of USP11—can effectively dismantle this defense, re-engage ferroptosis, and overcome resistance. This collective body of work underscores the “ubiquitin-ferroptosis axis” as a fundamental pillar of drug resistance in lung cancer and provides a compelling rationale for developing DUB-targeted therapies to resensitize refractory tumors. Head and neck tumors This section explores the critical roles of specific DUBs in mediating therapy resistance in head and neck tumors, primarily by stabilizing key anti-ferroptotic proteins to inhibit ferroptosis, thereby enabling cancer cell survival under chemotherapeutic or radiotherapeutic pressure (Fig. 3). Head and Neck Squamous Cell Carcinoma (HNSCC) USP14 (Ubiquitin-Specific Protease 14) promotes cisplatin resistance in Head and Neck Squamous Cell Carcinoma (HNSCC) by orchestrating a molecular pathway that effectively suppresses ferroptosis [126]. The mechanism is initiated by the observed overexpression of USP14 in HNSCC tissues and cell lines, which is further heightened in cisplatin-resistant cells. Functionally, USP14 directly interacts with and deubiquitinates Fatty Acid Binding Protein 5 (FABP5), a key player in lipid metabolism [126]. This deubiquitination action by USP14 removes ubiquitin chains from FABP5, thereby shielding it from proteasomal degradation and significantly enhancing its protein stability. The stabilized FABP5 protein subsequently acts to inhibit the ferroptosis process [126]. This is evidenced by a marked decrease in critical ferroptosis executors, including intracellular ferrous ions (Fe²⁺) and LOOH, along with an increase in the reduced-to-oxidized glutathione (GSH/GSSG) ratio. Furthermore, FABP5 upregulation leads to increased protein levels of the core anti-ferroptotic defenders SLC7A11 and GPX4. Consequently, by stabilizing FABP5, USP14 fortifies the cellular defense system against lethal lipid peroxidation, the hallmark of ferroptosis, thereby enabling HNSCC cells to survive cisplatin treatment [126]. The critical role of this axis was confirmed by rescue experiments, where overexpression of FABP5 counteracted the ferroptosis induction and proliferation defects caused by USP14 knockdown. Finally, the pharmacological inhibition of USP14 with the small molecule IU1 was shown to sensitize HNSCC tumors to cisplatin in vivo, validating the USP14-FABP5 axis as a pivotal mechanism conferring cisplatin resistance in HNSCC by negatively regulating ferroptosis [126]. Nasopharyngeal carcinoma (NPC) In nasopharyngeal carcinoma (NPC), the deubiquitinating enzyme UCHL1 mediates docetaxel resistance by stabilizing Caveolin-1 (CAV1) through deubiquitination, thereby inhibiting ferroptosis [127]. UCHL1, which is overexpressed in NPC tissues and cells, physically interacts with CAV1 and removes ubiquitin chains, preventing its proteasomal degradation [127]. This stabilization leads to increased CAV1 protein levels, which in turn suppresses key ferroptosis hallmarks: it reduces lipid reactive oxygen species (ROS) accumulation, decreases levels of malondialdehyde (MDA) and Fe²⁺, and upregulates the expression of the ferroptosis-related proteins SLC7A11 and GPX4. Consequently, the inhibition of ferroptosis enhances the survival of NPC cells under docetaxel treatment [127]. This mechanism is functionally significant, as silencing UCHL1 promotes CAV1 ubiquitination and degradation, restores ferroptosis sensitivity, and re-sensitizes docetaxel-resistant NPC cells to chemotherapy. Thus, the UCHL1/CAV1 axis represents a novel deubiquitination-driven pathway that confers chemoresistance in nasopharyngeal carcinoma by negatively regulating ferroptosis [127]. USP14 plays a central role in mediating ferroptosis resistance and radioresistance in nasopharyngeal carcinoma (NPC), but its function is paradoxically suppressed by the tumor suppressor GSTM3 to enhance radiosensitivity [128]. Unlike previous studies where USP14 acts as an oncogene by stabilizing substrates, here GSTM3 is upregulated after ionizing radiation (IR) and binds to USP14, leading to its stabilization [128]. This GSTM3-stabilized USP14 then deubiquitinates and stabilizes fatty acid synthase (FASN), a key enzyme in lipid biosynthesis. The stabilized FASN promotes the synthesis of polyunsaturated fatty acids, which are substrates for lipid peroxidation, thereby paradoxically contributing to the accumulation of LOOH and sensitizing cells to IR-induced ferroptosis. Simultaneously, GSTM3 independently interacts with and suppresses GPX4, a key antioxidant enzyme that repairs lipid peroxidation, thereby further promoting ferroptotic cell death [128]. Consequently, the GSTM3-USP14-FASN axis and GSTM3-GPX4 interaction work in concert to amplify lipid peroxidation and ferroptosis upon radiation, overcoming the traditional role of USP14 in promoting protein stability for survival. This mechanism significantly enhances the radiosensitivity of NPC cells, and low GSTM3 expression is clinically associated with tumor relapse and poor prognosis, highlighting the GSTM3-mediated suppression of USP14’s pro-survival function as a critical determinant of ferroptosis-dependent radiosensitization in nasopharyngeal carcinoma [128]. Gynecologic oncology, reproductive system tumor and other tumors This section explores how specific DUBs regulate ferroptosis to drive therapy resistance in gynecological cancers, reproductive system tumors, and other malignancies, detailing key DUB-substrate interactions that modulate cell death sensitivity across these cancers (Fig. 4). DUBs modulate ferroptosis to promote resistance across gynecologic cancers, reproductive system tumors, and other malignancies. This schematic overview presents the network of DUB-substrate interactions that inhibit ferroptosis, thereby conferring therapeutic resistance in a diverse range of cancers beyond the gastrointestinal and pulmonary systems, including breast cancer, cervical cancer, prostate cancer, bladder cancer, renal cell carcinoma, multiple myeloma, and melanoma Breast cancer USP30 promotes tamoxifen resistance in breast cancer by inhibiting ferroptosis through the stabilization of its substrate TOMM40, a key component of the mitochondrial outer membrane translocase complex [129]. USP30 is overexpressed in breast cancer and directly binds to TOMM40, removing its ubiquitin chains and preventing its proteasomal degradation [129]. This stabilization of TOMM40 enhances mitochondrial function and promotes a glycolytic phenotype, as evidenced by increased glucose consumption, lactate production, and ATP levels [129]. Crucially, the upregulated TOMM40 suppresses ferroptosis, an iron-dependent form of cell death, by reducing intracellular Fe²⁺ accumulation. Consequently, breast cancer cells become more resistant to tamoxifen-induced cytotoxicity [129]. Conversely, knockdown of either USP30 or TOMM40 sensitizes cells to tamoxifen by impairing glycolysis, elevating Fe²⁺ levels, and reactivating ferroptosis. Thus, the USP30-TOMM40 axis drives tamoxifen resistance in breast cancer primarily by shifting cellular metabolism and suppressing ferroptotic death [129]. Deubiquitinase OTUD5 promotes tumor progression and reduces paclitaxel sensitivity in triple-negative breast cancer (TNBC) by modulating ferroptosis through the stabilization of SLC7A11 [130]. Mechanistically, OTUD5 directly interacts with SLC7A11, and removes K48-linked polyubiquitin chains from SLC7A11, thereby preventing its proteasomal degradation and enhancing its protein stability [130]. This stabilization upregulates SLC7A11, which increases cystine uptake and promotes GSH synthesis, leading to suppression of lipid peroxidation and inhibition of ferroptosis—a form of iron-dependent regulated cell death. Consequently, OTUD5-mediated ferroptosis resistance facilitates TNBC cell survival, proliferation, and chemotherapy resistance [130]. In paclitaxel-treated TNBC, high OTUD5 expression correlates with reduced drug sensitivity, whereas OTUD5 knockdown enhances ferroptosis and restores chemosensitivity. This OTUD5-SLC7A11 -ferroptosis axis thus represents a key molecular mechanism underlying paclitaxel resistance in TNBC, highlighting the role of deubiquitination in regulating iron-mediated cell death and therapy response in this aggressive breast cancer subtype [130]. Cervical cancer USP31 plays a critical role in mediating radioresistance in cervical cancer by regulating the ferroptosis pathway through the stabilization of GPX4 [131]. Specifically, USP31 binds to and deubiquitinates GPX4, a key antioxidant enzyme that suppresses ferroptosis by reducing LOOH [131]. This deubiquitination prevents GPX4 from proteasomal degradation, thereby maintaining its protein levels and inhibitory effect on ferroptosis. When USP31 is knocked down, GPX4 undergoes increased ubiquitination and degradation, leading to the accumulation of lipid ROS, elevated intracellular Fe²⁺ levels, and heightened production of lipid peroxidation markers such as 4-HNE and MDA, alongside reduced GSH levels and NADPH/NADP⁺ ratios [131]. These changes promote ferroptosis, which enhances the sensitivity of cervical cancer cells to radiation. The mechanism is demonstrated in cervical cancer cell lines SiHa and HeLa, where USP31 depletion increases radiosensitivity, and this effect is reversed by GPX4 overexpression or the ferroptosis inhibitor Fer-1. Thus, USP31 confers radioresistance in cervical cancer by stabilizing GPX4 to inhibit ferroptosis, highlighting a targeted molecular pathway for potential therapeutic intervention [131]. Prostate cancer In prostate cancer, specifically castration-resistant prostate cancer (CRPC), the deubiquitinating enzyme USP19 plays a critical role in mediating tumor resistance by regulating ferroptosis through the stabilization of ACSL4, a key promoter of lipid peroxidation [132]. The molecular mechanism involves a palmitoylation -ubiquitination crosstalk orchestrated by the palmitoyltransferase ZDHHC2, which is transcriptionally upregulated by a FOXA1/CXXC5/TET2 complex in enzalutamide -resistant CRPC [132]. ZDHHC2 directly palmitoylates USP19 at the conserved cysteine 152 site. This palmitoylation modification weakens the interaction between USP19 and its substrate ACSL4. Under normal conditions, USP19 binds to ACSL4 and deubiquitinates it, specifically removing K48-linked polyubiquitin chains, thereby preventing its proteasomal degradation and stabilizing the ACSL4 protein. Stabilized ACSL4 promotes the esterification of polyunsaturated fatty acids into phospholipids, making them susceptible to peroxidation, which drives ferroptosis [132]. However, when USP19 is palmitoylated by ZDHHC2, its ability to bind and stabilize ACSL4 is impaired. This leads to increased ubiquitination and subsequent degradation of ACSL4 via the ubiquitin-proteasome system [132]. The loss of ACSL4 protein results in reduced lipid peroxidation and suppression of ferroptosis, enabling cancer cells to survive and conferring resistance to enzalutamide. This ZDHHC2-USP19-ACSL4 axis therefore identifies a novel mechanism in prostate cancer where palmitoylation of a deubiquitinase directly regulates the stability of a critical ferroptosis executor to promote therapy resistance [132]. Bladder cancer (BCa) This study elucidates that the deubiquitinating enzyme OTUB1 promotes cancer stem-like properties and drives drug resistance in Bladder Cancer (BCa) by directly suppressing ferroptosis [133]. The molecular mechanism is initiated by the significant upregulation of OTUB1 observed in BCa tissues and cell lines compared to normal controls. Functionally, OTUB1 exerts its oncogenic role by directly interacting with and deubiquitinating the core ferroptosis regulator SLC7A11, a key component of the System Xc- antiporter [133]. This deubiquitination event, specifically the removal of Lys48-linked polyubiquitin chains, prevents the proteasomal degradation of SLC7A11, thereby dramatically enhancing its protein stability and half-life. The stabilized SLC7A11 protein facilitates increased cystine uptake and subsequent synthesis of GSH, which is a crucial cofactor for the antioxidant enzyme GPX4 [133]. Consequently, this OTUB1-SLC7A11 axis potently inhibits the accumulation of lethal LOOH, a hallmark of ferroptosis, as evidenced by decreased levels of MDA, ROS, and intracellular iron. By creating this fortified anti-ferroptotic state, OTUB1 enables BCa cells, particularly the cancer stem cell (CSC) subpopulation, to survive and proliferate [133]. This is demonstrated by OTUB1’s ability to enhance the expression of stemness markers (SOX2, Oct4, NANOG, CD44) and increase sphere-forming capacity, which are key features of therapy-resistant CSCs. Crucially, the resistance conferred by this pathway is mechanistically dependent on SLC7A11, as its overexpression effectively rescues the impairment of stemness and the induction of ferroptosis caused by OTUB1 knockdown. In summary, in the context of bladder cancer, OTUB1 drives a drug-resistant and stem-like phenotype by deubiquitinating and stabilizing SLC7A11, which in turn fortifies the cellular defense against ferroptosis, highlighting the OTUB1-SLC7A11 axis as a pivotal mechanism of therapy resistance [133]. Renal clear cell carcinoma (RCCC) The deubiquitinase ZRANB1, traditionally known for its role in removing ubiquitin chains from substrate proteins, is revealed to function paradoxically as an E3 ubiquitin ligase for SLC7A11 [134]. This unconventional role enables ZRANB1 to promote the polyubiquitination and subsequent proteasomal degradation of SLC7A11, thereby reducing cystine uptake and impairing GSH synthesis [134]. The decrease in GSH levels leads to an accumulation of LOOH, a hallmark of ferroptosis, thereby sensitizing cancer cells to ferroptotic cell death. Importantly, this mechanism is demonstrated primarily in kidney renal clear cell carcinoma (KIRC), where ZRANB1 expression is often low, correlating with elevated SLC7A11 protein levels and increased resistance to ferroptosis inducers such as IKE [134]. Through both in vitro and in vivo models, including xenograft tumors and patient-derived samples, the study establishes that ZRANB1 deficiency contributes to ferroptosis resistance by stabilizing SLC7A11, while its overexpression restores sensitivity to ferroptosis, highlighting the ZRANB1-SLC7A11 axis as a critical regulator of ferroptotic vulnerability in KIRC [134]. Multiple myeloma (MM) The deubiquitinating enzyme USP14, facilitated by the molecular chaperone HSPA9, promotes tumor progression and confers therapy resistance in multiple myeloma (MM) by inhibiting ferroptosis through the stabilization of SLC7A11 [135]. Mechanistically, HSPA9, which is overexpressed in MM and correlates with poor prognosis, does not possess intrinsic deubiquitinase activity but functions as a critical scaffold protein that physically bridges USP14 and SLC7A11, enhancing their interaction [135]. This tripartite complex formation allows USP14 to specifically cleave K48-linked polyubiquitin chains from SLC7A11, thereby preventing its proteasomal degradation and increasing its protein stability. The stabilized SLC7A11, a core component of the cystine/glutamate antiporter system Xc⁻, enhances cystine uptake and subsequent glutathione (GSH) synthesis, which in turn suppresses lipid peroxidation and inhibits the iron-dependent cell death process of ferroptosis [135]. Consequently, this HSPA9/USP14-mediated ferroptosis resistance fuels MM cell survival, proliferation, and tumor growth [135]. The clinical relevance is underscored by the positive correlation between HSPA9, USP14, and SLC7A11 expression in MM patient samples and their association with worse overall survival. Furthermore, pharmacological inhibition of USP14 with IU1 promotes SLC7A11 ubiquitination and degradation, thereby inducing ferroptosis and suppressing tumor growth in MM xenograft models, highlighting the HSPA9-USP14-SLC7A11 axis as a key molecular mechanism underlying ferroptosis resistance and a promising therapeutic target in multiple myeloma [135]. Melanoma In uveal melanoma (UM), particularly in the metastatic form where BAP1 loss occurs in approximately 80% of cases, the deubiquitinase BAP1 plays a critical role in mediating resistance to ferroptosis—a form of regulated cell death driven by lipid peroxidation [136]. BAP1, in complex with ASXL2, functions as a histone H2A deubiquitinase, influencing epigenetic regulation and gene expression. Loss of BAP1 leads to destabilization of ASXL2, disrupting the BAP1/ASXL2 axis and resulting in altered lipid homeostasis [136]. This disruption reduces the expression of peroxisome proliferator-activated receptors (PPARα and PPARγ), which are key regulators of lipid metabolism [136]. Consequently, BAP1-mutant UM cells exhibit enhanced tolerance to lipotoxicity and accumulate fewer LOOH under polyunsaturated fatty acid (PUFA) exposure, thereby resisting ferroptotic cell death. This adaptive mechanism allows BAP1-deficient UM cells to survive and proliferate in the lipid-rich liver microenvironment, a common site of metastasis [136]. Importantly, this resistance can be therapeutically targeted using atorvastatin, an HMG-CoA reductase inhibitor, which induces lipid peroxidation and selectively kills BAP1-mutant UM cells, revealing a metabolic vulnerability linked to BAP1 loss and ferroptosis resistance in uveal melanoma [136]. USP7 mediates tumor resistance to ferroptosis by stabilizing the transcription factor JunD through direct deubiquitination, thereby promoting the expression of the key ferroptosis suppressor AIFM2 (also known as FSP1) [137]. Under normal conditions, USP7 binds to JunD and specifically cleaves its K48-linked polyubiquitin chains, preventing proteasomal degradation and enhancing JunD protein stability. Stabilized JunD then transcriptionally activates AIFM2, which functions as a CoQ10 reductase to regenerate the antioxidant form of coenzyme Q10, thereby reducing lipid peroxidation and suppressing ferroptosis [137]. This USP7-JunD-AIFM2 axis confers resistance to ferroptosis in melanoma cells, allowing them to survive under oxidative stress and contributing to tumor progression and therapy resistance [137]. Inhibition of USP7 disrupts this pathway, leading to JunD degradation, downregulation of AIFM2, increased lipid peroxidation, and enhanced ferroptosis sensitivity, both in vitro and in vivo. Thus, USP7 promotes ferroptosis resistance in melanoma by maintaining a protective antioxidant pathway via JunD-dependent AIFM2 expression [137]. MitoCur-1 overcomes vemurafenib resistance in melanoma by inducing ferroptosis through USP14 inhibition. This study identifies the deubiquitinating enzyme USP14 as a pivotal regulator of ferroptosis—an iron-dependent form of cell death—and further reveals its critical role in driving tumor resistance in the melanoma setting [138]. Specifically, the research demonstrates that USP14 is highly expressed in vemurafenib-resistant melanoma cells, and its inhibition by MitoCur-1 triggers ferroptosis, thereby reversing drug resistance. The molecular mechanism involves USP14’s interaction with and stabilization of GPX4, a critical negative regulator of ferroptosis [138]. Under normal conditions, GPX4 utilizes GSH to reduce LOOH, preventing the accumulation of lipid reactive oxygen species (ROS) and subsequent ferroptosis. However, when USP14 is inhibited by MitoCur-1, the expression and activity of GPX4 are suppressed, leading to decreased GSH levels, accumulation of ferrous iron (Fe²⁺), and elevated lipid ROS [138]. This cascade promotes ferroptotic cell death. Importantly, overexpression of USP14 reverses these effects, confirming its central role in regulating ferroptosis. Additionally, USP14 inhibition downregulates SLC7A11, further impairing GSH synthesis and amplifying ferroptosis [138]. This mechanism highlights how targeting USP14 disrupts the redox balance and iron metabolism in melanoma cells, making them susceptible to ferroptosis and overcoming resistance to BRAF inhibitors like vemurafenib. Thus, in melanoma, USP14 acts as a pivotal mediator of drug resistance by suppressing ferroptosis through stabilization of GPX4 and modulation of the system Xc⁻-GSH-GPX4 axis [138]. In this section, the key findings highlight how specific DUBs such as USP20, OTUB1, USP14, USP7, and others stabilize critical ferroptosis regulators (e.g., SLC7A11, GPX4, NRF2, ACSL4) across various cancers, thereby conferring resistance to chemotherapeutic agents, targeted therapies, and radiotherapy. These DUBs often function through deubiquitination-mediated stabilization of anti-ferroptotic proteins, and their activities are frequently modulated by upstream signaling or stress responses, creating feedback loops that reinforce resistance. Despite these insights, several unresolved issues remain. The context-dependent roles of many DUBs in different cancer types or under varying therapeutic pressures are not fully elucidated, and the functional redundancy or crosstalk among DUBs in regulating ferroptosis remains poorly understood. Moreover, the translational gap between mechanistic studies and clinical application is significant—most findings are preclinical, with a lack of potent and selective DUB inhibitors suitable for human trials. Future research should focus on identifying pan-cancer and tissue-specific DUB networks, developing isoform-specific DUB inhibitors, and exploring combination therapies that simultaneously target DUBs and conventional treatments to overcome resistance. Additionally, understanding how tumor microenvironmental factors influence DUB activity and ferroptosis sensitivity will be critical for designing effective therapeutic strategies. Hypoxia-mediated regulation of DUB-ferroptosis axis in drug resistance Tumor hypoxia is a pervasive feature of the tumor microenvironment (TME) that drives aggressive phenotypes, metabolic reprogramming, and therapy resistance. The adaptive response to low oxygen, primarily orchestrated by hypoxia-inducible factors (HIFs), profoundly influences ferroptosis susceptibility. However, the dynamic regulation of deubiquitinating enzymes (DUBs) under hypoxic conditions and their impact on ferroptosis-mediated drug resistance remain underexplored. While the previous section highlighted USP2 downregulation in hypoxic esophageal squamous cell carcinoma (ESCC) leading to NCOA4 degradation and ferroptosis suppression [124], emerging evidence indicates that hypoxia rewires a broader network of DUBs and ferroptosis regulators in a spatiotemporally dynamic manner. Hypoxic stress directly modulates the expression and activity of multiple DUBs through HIF-1α-dependent and -independent mechanisms. For instance, HIF-1α transcriptionally represses USP2 in ESCC, but conversely stabilizes USP14 in several cancer types via post-translational mechanisms [112, 125]. More importantly, HIF-1α orchestrates lipid remodeling that alters ferroptosis tolerance. Under chronic hypoxia, cancer cells accumulate monounsaturated fatty acids (MUFAs) and reduce polyunsaturated fatty acid (PUFA) incorporation into phospholipids, a process dependent on HIF-1α-induced expression of stearoyl-CoA desaturase 1 (SCD1) and suppression of ACSL4 [118, 132]. This lipid profile intrinsically resists lipid peroxidation, creating a ferroptosis-resistant state. DUBs critically mediate this adaptation: USP7 stabilizes SCD in gastric cancer [118] while USP19’s palmitoylation status determines ACSL4 stability in prostate cancer [132], both under hypoxia-mimicking conditions. Furthermore, spatial heterogeneity of oxygenation within tumors generates gradients of DUB activity. Perinecrotic and central hypoxic regions often exhibit elevated HIF-1α and its target DUBs (e.g., USP14, USP7), whereas better-oxygenated peripheral zones may show lower DUB expression [115, 123]. This spatial segregation leads to distinct ferroptosis sensitivities across tumor subregions, contributing to clonal selection during therapy. For example, in hepatocellular carcinoma, USP14 is highly enriched in hypoxic cores, conferring radioresistance by stabilizing GPX4 [112]; conversely, reoxygenation after radiotherapy rapidly downregulates USP14, restoring ferroptosis susceptibility. Such dynamic oscillations in DUB levels and ferroptosis defense likely underpin adaptive resistance and tumor relapse. Mechanistically, HIF-1α directly binds to hypoxia response elements (HREs) in the promoters of several DUB genes. Transcriptomic analyses have identified USP14, USP7, OTUB1, and USP20 as putative HIF-1α targets, though validation of direct HRE binding varies across cell types [110, 116, 137]. Additionally, hypoxia induces lysosomal sequestration and autophagic degradation of certain DUBs (e.g., USP2, USP5) through HIF-1α-mediated upregulation of lysosomal proteases [117, 124]. This degradation is reversible upon reoxygenation, enabling rapid switching between ferroptosis-resistant and -sensitive states. The clinical relevance of hypoxia-DUB-ferroptosis crosstalk is underscored by correlative studies. High expression of HIF-1α together with USP14 or USP7 predicts poor response to chemotherapy and radiotherapy in multiple cancer types [112, 118, 126]. Conversely, tumors with low hypoxic fractions but high DUB activity may paradoxically remain ferroptosis-sensitive due to adequate oxygen supply for lipid peroxidation. Therefore, targeting DUBs in combination with hypoxia-activated prodrugs or HIF-1α inhibitors represents an emerging strategy to re-sensitize resistant tumors. Future studies should employ single-cell and spatial transcriptomics to map DUB-ferroptosis landscapes across oxygen gradients and develop DUB inhibitors that are effective under both normoxic and hypoxic conditions. DUB inhibitors targeting ferroptosis in cancer: current status and clinical prospects Given the central role of DUBs in stabilizing anti-ferroptotic proteins and driving therapy resistance, pharmacological inhibition of these enzymes has emerged as a promising strategy to re-sensitize resistant tumors. Several small-molecule DUB inhibitors have been developed and evaluated in preclinical models, some of which directly impact ferroptosis sensitivity. USP14 inhibitors are among the most extensively studied. IU1, a selective USP14 inhibitor, has been shown to promote GPX4 degradation and induce ferroptosis in HCC, ESCC, HNSCC, and MM [112, 125, 126, 135]. In melanoma, the novel compound MitoCur-1 inhibits USP14, leading to GPX4 suppression and reversal of vemurafenib resistance [138]. Another USP14/UCHL5 dual inhibitor, b-AP15, has demonstrated anti-tumor activity in various solid tumors and hematologic malignancies by disrupting the ubiquitin-proteasome system, though its direct effect on ferroptosis remains to be fully characterized [139, 140]. VLX1570, a second-generation inhibitor of USP14 and UCHL5, entered early clinical trials for multiple myeloma but was discontinued due to toxicity; however, it provides a proof-of-concept for targeting DUBs in cancer [141]. USP7 inhibitors have shown particular promise. FT671 and GNE-6640 are selective, non-covalent USP7 inhibitors that induce p53 stabilization and exhibit anti-tumor activity in p53-wild-type cancers [142, 143]. Given that USP7 stabilizes SCD in gastric cancer and JunD in melanoma to suppress ferroptosis, these inhibitors may also trigger ferroptosis by destabilizing those substrates [118, 137]. P22077, another USP7 inhibitor, has been reported to increase lipid peroxidation and enhance ferroptosis in preclinical models, though its selectivity requires further optimization [144]. Pan-DUB inhibitors like PR-619 are valuable research tools but suffer from off-target toxicity, limiting their clinical utility. Nevertheless, they have helped establish the feasibility of targeting DUBs for ferroptosis induction [145]. Despite these advances, several obstacles hinder clinical translation: (1) high structural homology among DUB family members makes isoform-selective inhibitor design challenging; (2) many current inhibitors have suboptimal pharmacokinetic properties or toxicity profiles; (3) the functional consequence of DUB inhibition is often cell-context dependent, necessitating predictive biomarkers. Future efforts should focus on structure-guided development of next-generation DUB inhibitors, combination strategies with ferroptosis inducers or conventional chemotherapies, and biomarker-driven clinical trials to identify patients most likely to benefit. Concluding remarks and prospects Cancer drug resistance remains a formidable challenge in clinical oncology, significantly undermining the efficacy of conventional chemotherapies, targeted agents, and immunotherapies. In recent years, ferroptosis has emerged as a critical tumor suppression mechanism and a promising avenue to overcome therapy resistance. This review has systematically elucidated the pivotal role of DUBs in fine-tuning the ferroptotic process through PTMs, thereby shaping the drug-resistant phenotype across various cancer types. DUBs exert precise and dynamic control over core components of the ferroptosis pathway, including SLC7A11, GPX4, NRF2, ACSL4, and FSP1, among others. By removing ubiquitin chains, DUBs such as USP20, OTUB1, USP14, and USP7 enhance the stability and activity of these regulators, enabling cancer cells to evade ferroptotic death. For instance, in hepatocellular carcinoma, USP20 stabilizes SLC7A11 to sustain glutathione synthesis, while in lung and colorectal cancers, OTUB1 and USP14 protect GPX4 from degradation, fortifying cellular antioxidant defenses. These mechanisms are often amplified under therapeutic stress, such as chemotherapy or radiation, where DNA damage or oxidative signals further activate DUB-mediated pro-survival pathways. The regulatory scope of DUBs extends beyond canonical deubiquitination, involving cross-talk with phosphorylation, acetylation, ISGylation, and even non-catalytic roles, as exemplified by USP5 in colorectal cancer. Such complexity underscores the adaptability of cancer cells and highlights DUBs as central nodes in the resistance network. Therapeutic targeting of DUB-ferroptosis interactions holds immense potential. Preclinical studies have demonstrated that genetic knockdown or pharmacological inhibition of specific DUBs—such as USP14, USP7, or OTUB1—can resensitize resistant tumors to standard therapies by reactivating ferroptosis. Small-molecule inhibitors like GSK2643943A, IU1, and DUB-IN-3 have shown promise in restoring drug sensitivity in vitro and in vivo. However, several challenges remain. The high structural similarity among DUB family members raises concerns about selectivity and potential off-target effects. Moreover, the functional outcomes of DUB inhibition may be context-dependent, influenced by cancer type, genetic background, and tumor microenvironment. For example, while USP22 generally promotes resistance in HCC and NSCLC, its role may vary in other malignancies due to substrate specificity and signaling crosstalk. Beyond efficacy, the translational application of DUB inhibitors combined with ferroptosis inducers must carefully consider potential on-target off-tumor toxicity. Notably, USP14 and USP7 play indispensable physiological roles in normal tissues. USP14 is a critical regulator of neuronal proteostasis and synaptic function; its deficiency or chronic inhibition has been linked to impaired autophagy and neurodegenerative phenotypes in animal models [146]. Similarly, USP7 is essential for hematopoietic stem cell maintenance and lymphocyte development, and systemic USP7 inhibition may cause hematological adverse effects [147, 148]. Since ferroptosis induction itself can affect multiple organs, the combination of DUB inhibition with ferroptosis inducers could exacerbate collateral damage to vulnerable normal tissues such as the brain and bone marrow. Therefore, tumor-selective strategies are urgently needed to improve the therapeutic window. One promising approach is the use of proteolysis-targeting chimeras (PROTACs) designed to degrade oncogenic DUBs specifically within cancer cells. Recent advances have yielded first-in-class PROTACs targeting USP7 and USP14, which achieve sustained target knockdown with reduced systemic exposure compared to conventional small-molecule inhibitors [149]. Alternatively, nanoparticle-based targeted delivery systems—such as antibody -conjugated liposomes or tumor microenvironment-responsive polymers —can encapsulate DUB inhibitors or ferroptosis inducers to preferentially accumulate in malignant lesions [150]. These strategies not only enhance antitumor efficacy but also limit ferroptosis-associated damage to normal tissues. Future preclinical studies should systematically evaluate the safety profile of DUB inhibition combined with ferroptosis induction in immunocompetent mouse models, incorporating tissue -specific conditional knockout systems to distinguish on-target toxicity from off-target effects. Such efforts will be critical to translate the ubiquitin–ferroptosis axis into clinically viable therapies with an acceptable therapeutic index. Looking forward, several directions warrant further investigation. First, a deeper understanding of the structural basis of DUB-substrate interactions will facilitate the design of more selective inhibitors. Second, the interplay between DUBs and other PTMs—such as phosphorylation, acetylation, and palmitoylation—adds layers of regulation that remain underexplored. For instance, the palmitoylation of USP19 in prostate cancer modulates its ability to stabilize ACSL4, illustrating how lipid metabolism and ubiquitination converge to regulate ferroptosis. Third, the role of DUBs in the tumor microenvironment—particularly in immune cells and stromal compartments—may influence both ferroptosis susceptibility and immunotherapy response, opening new avenues for combination therapies.Furthermore, the clinical translation of DUB inhibitors will require robust biomarkers to identify patient populations most likely to benefit. Expression levels of specific DUBs or their substrates (e.g., SLC7A11, GPX4) could serve as predictive markers for ferroptosis-inducing regimens. Additionally, combining DUB inhibitors with ferroptosis inducers (e.g., erastin, RSL3, sorafenib) or conventional chemotherapies may yield synergistic effects, particularly in tumors with inherent or acquired resistance. In conclusion, the regulation of ferroptosis by DUBs represents a sophisticated and actionable mechanism underlying cancer drug resistance. As our molecular understanding deepens, targeting the ubiquitin-ferroptosis axis offers a promising strategy to reprogram cell fate and eliminate resistant cancers. Future efforts should focus on translating these insights into clinically viable therapies, ultimately improving outcomes for patients with refractory malignancies. Acknowledgements Not applicable. Abbreviations Acyl-CoA synthetase long-chain family member 4 Acetyl-CoA carboxylase AMP-activated protein kinase Acyl-CoA Thioesterase 7 Deubiquitinating enzymes Dihydroorotate dehydrogenase Dihydrofolate reductase Ferroptosis Suppressor Protein 1 Ferroportin1 Glutathione Glutathione peroxidase 4 GTP cyclohydrolase 1 Histone deacetylases Lipid peroxidation Lipopolysaccharide Lectin-like oxidized low-density lipoprotein receptor-1 Lysophosphatidylcholine acyltransferase 3 Malondialdehyde Mitogen-Activated Protein Kinase 2 Monounsaturated fatty acids Nuclear receptor coactivator 4 Nuclear factor erythroid 2-related factor 2 Phosphatidylethanolamine Polyunsaturated fatty acids Polyunsaturated fatty acid phospholipid Peroxidized derivatives Post-translational modifications Regulated cell death Stearoyl-CoA Desaturase Transferrin receptor Author contributions XJ, XH and HS conceived of and designed the study. XJ and HS performed methodology, data curation, formal analysis, and visualization. XH provided administrative support. XJ and HS wrote the manuscript. YW edited the manucsript. All authors analysed and interpreted the data. All authors read and approved the final manuscript. Funding This work was supported in part by the Natural Science Foundation of Inner Mongolia Autonomous Region (2023LHMS08050). Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Huiyan Sun, Email: shy1980_1981@163.com. Hao Lian, Email: lian_h0706@163.com. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.